Owkin
Applies federated learning and AI to biological data for drug discovery and diagnostics.
What they do
Owkin utilizes federated machine learning to analyze decentralized patient data without compromising privacy. Pharmaceutical enterprises and academic medical centers use this platform to discover novel cancer therapies, optimize clinical trial design, and develop advanced diagnostic tools for oncology and immunology.
The record
- Vertical
- Oncology
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Paris, France
- Region
- Europe
- Founded
- 2016
- Total funding
- $304M raised
Notable investors: Sanofi, Mubadala Investment Company, BPIFrance, Cathay Innovation.